Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Retained Earnings (2021 - 2025)

Bioventus' Retained Earnings history spans 5 years, with the latest figure at -$1.9 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.47% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached -$1.9 million, up 99.47%, while the annual FY2025 figure was -$1.9 million, 99.47% up from the prior year.
  • Retained Earnings reached -$1.9 million in Q4 2025 per BVS's latest filing, down from -$1.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $655000.0 in Q3 2023 to a low of -$360.3 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$102.7 million, with a median of -$1.9 million recorded in 2025.
  • Peak YoY movement for Retained Earnings: surged 102.61% in 2023, then tumbled 110960.92% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $179000.0 in 2021, then tumbled by 92449.72% to -$165.3 million in 2022, then tumbled by 94.51% to -$321.5 million in 2023, then dropped by 11.24% to -$357.7 million in 2024, then soared by 99.47% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Retained Earnings are -$1.9 million (Q4 2025), -$1.8 million (Q3 2025), and -$774000.0 (Q2 2025).